GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Subgen AI SUBGEN.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

0.03

+5.33%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Subgen AI

Its shares trade on Nasdaq Stockholm under the ticker SUBGEN.ST. It has been listed since 26 June 2020. In the fiscal year to 31 December 2025, it reported revenue of SEK 204.4m and a net loss of SEK 88.9m. At that date it held total assets of SEK 617.8m and shareholders' equity of SEK 418.7m.

AegirBio AB engages in the development and commercialization of drug monitoring tests. The company is headquartered in Lund, Skane. The company went IPO on 2020-06-26. The firm offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. The company aims to provide personalized treatment by tracking drugs levels in individuals. Aegirbio combines core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Sweden, which owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a California-based biotech, which is a developer of the Veritope chemistry platform for detecting levels of biologic drugs in patient samples.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
26 Jun 2020
Employees
1

Leadership

Pay as last reported

  • Mr. Jens UmehagIndependent Chairman of the Board
  • Mr. Marco WitteveenChief Executive Officer, Executive Director, since 2023SEK 1.5m
  • Ms. Vicki JohnsonInterim Chief Financial Officer
  • Dr. Vasiliki FragkouChief Operating Officer
  • Mr. William FerenczyIndependent Director
  • Mr. Fredrik HaglundIndependent DirectorSEK 105,000
  • Mr. Michael SchwartzIndependent Director
  • Mr. William VickeryIndependent DirectorSEK 105,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Subgen AI AB develops drug monitoring tests using patented technology for personalized treatment.
  • AegirBio combines LifeAssays and Abreos Biosciences core technologies for drug level tracking.
  • Lund, Skane headquarters supports biotechnology innovation in Sweden.

Weaknesses

  • AegirBio has only one employee limiting operational capacity.
  • The company's IPO on 26 June 2020 shows limited market presence.
  • Subgen AI AB lacks a large product portfolio for diverse market needs.

Opportunities

  • Expanding drug monitoring tests in the Health Care sector across Europe.
  • Growing demand for personalized treatment in the Biotechnology industry.
  • Collaborating with LifeAssays and Abreos Biosciences for technology enhancement.

Threats

  • Competition from established biotech firms in the Health Care sector.
  • Regulatory changes affecting drug monitoring in the Biotechnology industry.
  • Economic downturns impacting Health Care sector investments.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.